Paper Details

  1. Home
  2. Paper Details

Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.

Author: AndersenElisabeth W, CareyPaul D, FinebergNaomi, LochnerChristine, SeedatSoraya, SteinDan J

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated how different symptoms of obsessive-compulsive disorder (OCD) responded to 12 weeks of treatment with escitalopram or a placebo. Previous research has shown that different OCD symptoms are distinct and may respond differently to treatment.
Paper Details　
Original Abstract of the Article :
There is a substantial body of evidence that obsessive-compulsive disorder (OCD) symptoms can be grouped into a series of discrete dimensions, and some evidence that not all OCD symptom dimensions respond equally well to pharmacologic or psychotherapeutic intervention. The response of OCD symptom di...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1017/s1092852900016722

データ提供：米国国立医学図書館（NLM）

Escitalopram: A Targeted Approach to Obsessive-Compulsive Disorder (OCD)

This study explores the complex world of obsessive-compulsive disorder (OCD), a chronic mental health condition characterized by intrusive thoughts and repetitive behaviors. The study investigates the effectiveness of escitalopram, a selective serotonin reuptake inhibitor (SSRI), in treating OCD and examines the specific symptom dimensions that respond well to this medication. This research delves into the intricate relationship between serotonin and OCD, highlighting the potential for targeted pharmacotherapy.

Escitalopram Shows Promise in Treating OCD

The study reveals that escitalopram demonstrates efficacy in reducing OCD symptoms, particularly in specific dimensions like obsessions and compulsions. This finding suggests that escitalopram may be a valuable treatment option for individuals with OCD, offering potential for symptom relief and improved quality of life. The study's rigorous design, employing a placebo-controlled trial, further strengthens its conclusions and provides valuable insights into the therapeutic potential of escitalopram for OCD.

Navigating OCD: A Journey Through Intrusive Thoughts

OCD can be a challenging and debilitating condition, often interfering with daily life and creating significant distress. This study offers hope for those struggling with OCD, presenting escitalopram as a potentially effective treatment option. It's like finding a guiding star in the desert of OCD, offering a path towards symptom reduction and a more manageable experience. This research underscores the importance of understanding the complex nature of OCD and developing targeted treatments for this prevalent mental health condition.

Dr.Camel's Conclusion

This study provides valuable insights into the effectiveness of escitalopram in treating OCD. It's like finding a secret oasis in the vast desert of mental illness, offering a refuge from the debilitating effects of OCD. This research highlights the potential of targeting specific symptom dimensions with tailored pharmacotherapy, offering hope for improved outcomes for individuals struggling with this condition.
Date :
  1. Date Completed 2008-08-18
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

18567973

DOI: Digital Object Identifier

10.1017/s1092852900016722

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.